BioSpace News Archive

The Prix Galien USA Committee last night honored excellence in the biopharmaceutical and medical industry for research, development and innovation at its 13th annual Prix Galien Awards Gala, held at the American Museum of Natural History in New York City.

Microbion Corporation of Bozeman, MT, and Microbion Pharma Corp. of Vancouver, BC (“Microbion”) today announced that the World Health Organization (WHO) has recommended “pravibismane” as the International Nonproprietary Name (INN), also commonly known as a generic name, for Microbion’s lead broad-spectrum antimicrobial and antibiofilm agent.

Acknowledging the one-year anniversary of the signing of HR 6—the historic federal legislation aimed at curbing the opioid epidemic, DisposeRx is well on its way to making good on its pledge to remove over 10 million opioid pills from our nation’s medicine cabinets.

Imago BioSciences, Inc., a clinical-stage biotechnology company focused on the treatment of myeloproliferative neoplasms (MPN) and related bone marrow diseases, announced today that preliminary data from its ongoing Phase 2 study of IMG-7289 (bomedemstat) in patients with myelofibrosis (MF) has been selected for an oral presentation at the American Society of Hematology (ASH) Annual Meeting, on December 9 in Orlando, Florida.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Nicolas M. Barthelemy to its board of directors.

Nearly two years of real-world outcomes data on Abiomed’s (NASDAQ: ABMD) Impella RP heart pump shows that when physicians followed the FDA’s approved protocol for Impella RP use they achieved 72% patient survival and 88% native heart recovery.

AbbVie Inc. (NYSE:ABBV) (“AbbVie”) announced today the commencement, in connection with its previously announced acquisition of Allergan plc

Teladoc Health, the global leader in virtual care, announces the U.S. launch of Teladoc Medical Experts, the first-of-its-kind, broad-based virtual center of excellence for individuals dealing with a wide range of complex and/or costly mental and physical medical needs.

BEDFORD, Mass., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the oral presentation of preclinical data related to its nuclease-free, homologous recombination-based, in vivo gene editing program for phenylketonuria (PKU) at the European Society of Gene & Cell Therapy (ESGCT) 27th Annual Congress. Homology also presented preclinical data that showed the effect of full and empty capsids on in vivo efficacy with Hom

Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has entered into a $20.0 million common stock purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor.